Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.
Overview
In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]
As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]
References
- Alder BioPharmaceuticals stock flat after unexciting IPO geekwire.com, 8 May 2014, retrieved 24 August 2017^
- Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma Drug Development Technology, Kable, 2 February 2018, retrieved 3 February 2018^
- Alder Biopharmaceuticals Inc - Company Profile and News Bloomberg.com, retrieved 2019-05-21^
- Tomi Kilgore. Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal Market Watch, 2019-09-16, retrieved 2019-10-21^
- Alder BioPharma, Bothell developer of migraine-prevention drug, acquired for up to $2 billion The Seattle Times, retrieved 2020-06-18^
- Janice Podsada. Bay Area bio-tech firm to open production plant in Bothell The Everett Herald, August 5, 2020, retrieved February 19, 2022^